Alkermes plc. Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount
Alkermes plc. (ALKS) reported Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount of $6.97 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationTaxCreditsResearch · last filed 2026-02-25
- Alkermes plc. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2025 was $6.97M, a 10.75% decline from fiscal 2024.
- Alkermes plc. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2024 was $7.82M, a 176.83% increase from fiscal 2023.
- Alkermes plc. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2023 was $2.82M, a 11.54% increase from fiscal 2022.
- Alkermes plc. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2022 was $2.53M, a 11.84% decline from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount 9 month | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount 12 month | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount 12 month as first filed |
|---|---|---|---|
| 2025-12-31 | $6.97M 10-K · filed 2026-02-25 | ||
| 2024-12-31 | $7.82M 10-K · filed 2026-02-25 | ||
| 2023-12-31 | $2.82M 10-K · filed 2026-02-25 | ||
| 2022-12-31 | $2.53M 10-K · filed 2025-02-12 | $7.86M 10-K · filed 2023-02-16 | |
| 2021-12-31 | $2.87M 10-K · filed 2024-02-21 | $8.49M 10-K · filed 2022-02-16 | |
| 2020-12-31 | $11.20M 10-K · filed 2023-02-16 | ||
| 2019-12-31 | $8.85M 10-K · filed 2022-02-16 | ||
| 2018-12-31 | $7.70M 10-K · filed 2021-02-11 | ||
| 2017-12-31 | $9.33M 10-K · filed 2020-02-13 | ||
| 2016-12-31 | $10.57M 10-K · filed 2019-02-15 | ||
| 2015-12-31 | $12.19M 10-K · filed 2018-02-16 | ||
| 2014-12-31 | $14.01M 10-K · filed 2017-02-17 | ||
| 2013-12-31 | $1.60M 10-K · filed 2016-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |